Holly Dawson
Primary Care · Pittsburgh, PANPI 1356852925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,692 and has fallen 97.5% since, to $42 in 2025. Among primary care clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$632
- GSK$552
- Pfizer$361
- Boehringer Ingelheim$283
- Bayer$283
- Lilly USA, LLC$266
- plus $2K from 21 others
What the payments were for
- Food & beverage$3,99998%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $632 |
| GSK | 32 | $552 |
| Pfizer | 20 | $361 |
| Boehringer Ingelheim | 16 | $283 |
| Bayer | 18 | $283 |
| Lilly USA, LLC | 15 | $266 |
| Johnson & Johnson | 15 | $235 |
| Abbott | 12 | $225 |
| AbbVie | 7 | $183 |
| Astellas Pharma US Inc | 4 | $156 |
| Novartis | 7 | $113 |
| AstraZeneca | 7 | $112 |
| Merck | 6 | $106 |
| Exact Sciences | 5 | $101 |
| Dexcom, Inc. | 5 | $70 |
| Philips North America LLC | 4 | $70 |
| Amgen | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Corcept Therapeutics | 1 | $29 |
| Edwards Lifesciences | 1 | $29 |
| UCB, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$4,099 in reported general payments places this provider in the 90th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 21 | $25,251 |
| MounjaroTirzepatide | 18 | $20,896 |
| EliquisApixaban | 13 | $17,259 |
| JardianceEmpagliflozin | 15 | $16,538 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,255 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $12,403 |
| JanuviaSitagliptin Phosphate | 12 | $9,730 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,840 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,527 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,747 |
| Gabapentin | 118 | $1,695 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,692 |
| Celecoxib | 24 | $1,185 |
| Atorvastatin Calcium | 172 | $1,180 |
| Tamsulosin Hcl | 55 | $828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $552 | $33,49866 claims |
| Novo NordiskRybelsus | $632 | $25,25121 claims |
| Lilly USA, LLCMounjaro | $266 | $20,89618 claims |
| PfizerEliquis | $361 | $17,25913 claims |
| Boehringer IngelheimJardiance | $283 | $16,53815 claims |
| MerckJanuvia | $106 | $9,73012 claims |
| AbbVieSynthroid | $183 | $80717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Pittsburgh
- Cara CaranoPittsburgh$2K
- Kersten ReiderMount Penn$121K
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Mollie McGuireJohnstown$11K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Minjung RegerDoylestown$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.